Literature DB >> 4016498

The radiosensitivity of human neuroblastoma cells estimated from regrowth curves of multicellular tumour spheroids.

T E Wheldon, A Livingstone, L Wilson, J O'Donoghue, A Gregor.   

Abstract

Multicellular tumour spheroids may provide a suitable in-vitro model for micrometastases in vivo. In this paper, the results are reported of experimental studies on the radiation response of two lines of spheroids derived from human neuroblastoma. Spheroids of approximately 200-250 microM mean diameter were exposed to graded doses of X rays (50-350 cGy) and, following a static or regression phase, regrew at rates which approximated those of unirradiated spheroids. Clonogenic surviving fraction was estimated, at each dose level, by extrapolation of the regrowth curve to zero dose. It is proposed that this procedure is more suitable for regrowth curves of spheroids than in-vivo tumours, because of the absence in vitro of complicating factors which occur only in vivo. By this means, survival curves were deduced and were found (for both cell lines) to be almost exponential in form, with little indication of capacity for accumulation of sublethal damage (multitarget parameters: DQ values: 17 and 25 cGy; Do values: 104 and 81 cGy respectively). These results contribute to the evidence for high radiosensitivity of neuroblastoma cells in vitro and provide a rationale for the use of hyperfractionation in the clinical treatment of neuroblastoma by radiotherapy.

Entities:  

Mesh:

Year:  1985        PMID: 4016498     DOI: 10.1259/0007-1285-58-691-661

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  7 in total

1.  Incorporation of iododeoxyuridine in multicellular glioma spheroids: implications for DNA-targeted radiotherapy using Auger electron emitters.

Authors:  A Neshasteh-Riz; W J Angerson; J R Reeves; G Smith; R Rampling; R J Mairs
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

2.  The uptake and retention of metaiodobenzyl guanidine by the neuroblastoma cell line NB1-G.

Authors:  R J Mairs; M N Gaze; A Barrett
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

3.  Biological properties of a tumour cell line (NB1-G) derived from human neuroblastoma.

Authors:  R Carachi; T Raza; D Robertson; T W Wheldon; L Wilson; A Livingstone; V van Heyningen; G Spowart; P Middleton; J R Gosden
Journal:  Br J Cancer       Date:  1987-04       Impact factor: 7.640

4.  Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions.

Authors:  S H Cunningham; R J Mairs; T E Wheldon; P C Welsh; G Vaidyanathan; M R Zalutsky
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

5.  A tumour spheroid model for antibody-targeted therapy of micrometastases.

Authors:  K A Walker; T Murray; T E Hilditch; T E Wheldon; A Gregor; I M Hann
Journal:  Br J Cancer       Date:  1988-07       Impact factor: 7.640

6.  131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes.

Authors:  M N Gaze; R J Mairs; S M Boyack; T E Wheldon; A Barrett
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

7.  Deriving cell survival curves from the overall responses of irradiated tumours: analysis of published data for tumour spheroids.

Authors:  J V Moore; C M West; J H Hendry
Journal:  Br J Cancer       Date:  1987-09       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.